Stockscreener 앱 받기
62.95
1.22%
0.76
시간 외 거래:
62.35
-0.60
-0.95%
전일 마감가:
$62.19
열려 있는:
$62
하루 거래량:
1.84M
Relative Volume:
0.93
시가총액:
$7.75B
수익:
$88.04M
순이익/손실:
$-784.96M
주가수익비율:
-9.635
EPS:
-6.5335
순현금흐름:
$-534.82M
1주 성능:
+4.92%
1개월 성능:
-7.19%
6개월 성능:
+29.37%
1년 성능:
+44.88%
1일 변동 폭
$61.53
$63.80
1주일 범위
$58.43
$63.80
52주 변동 폭
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
62.95 | 7.66B | 88.04M | -784.96M | -534.82M | -6.5335 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-12-18 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-07-30 | 재개 | Raymond James | Mkt Perform |
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Sung Lee Sells 4,935 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 1,930 Shares of Stock - MarketBeat
Blum, Cytokinetics CEO, sells $2.2m in shares By Investing.com - Investing.com Canada
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 36,601 Shares of Stock - MarketBeat
Andrew Callos Sells 8,542 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Malik Fady Ibraham sells Cytokinetics (CYTK) stock worth $747,850 - Investing.com
Cytokinetics Insiders Sold Shares Worth Over $3.6M - TradingView
Cytokinetics (CYTK) CFO share sale covers RSU tax obligations - Stock Titan
Mizuho Raises Price Target for Cytokinetics (CYTK) to $100 | CYT - GuruFocus
Cytokinetics (CYTK) EVP executes 8,542-share sell-to-cover for RSU taxes - Stock Titan
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
Cytokinetics President & CEO Sold Shares Worth Over $2.2M - TradingView
Cytokinetics (CYTK) CEO executes sell-to-cover stock sales for taxes - Stock Titan
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cytokinetics gives 5 new hires options, RSUs under Nasdaq rule - Stock Titan
Mizuho Boosts Cytokinetics (NASDAQ:CYTK) Price Target to $100.00 - MarketBeat
Mizuho Raises Price Target for Cytokinetics (CYTK) to $100 | CYTK Stock News - GuruFocus
New Aficamten HCM Data On Exercise Capacity And Flexibility Might Change The Case For Investing In Cytokinetics (CYTK) - simplywall.st
Cytokinetics (CYTK) CEO receives new RSU and stock option awards - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Cytokinetics (CYTK) EVP awarded new stock options and RSUs - Stock Titan
Cytokinetics (CYTK) awards stock options and RSUs to chief legal officer - Stock Titan
Cytokinetics (CYTK) CFO granted RSUs and stock options - Stock Titan
JPMorgan Chase & Co. Raises Cytokinetics (NASDAQ:CYTK) Price Target to $75.00 - MarketBeat
CYTK Analyst Update: JP Morgan Raises Price Target to $75 | CYTK Stock News - GuruFocus
Cytokinetics stock price target raised to $75 by JPMorgan - Investing.com Canada
JPMorgan Boosts Price Target on Cytokinetics (CYTK) Amid Positive Outlook - GuruFocus
Granahan Investment Management LLC Purchases Shares of 53,550 Cytokinetics, Incorporated $CYTK - MarketBeat
Bamco Inc. NY Makes New Investment in Cytokinetics, Incorporated $CYTK - National Today
Assessing Cytokinetics (CYTK) Valuation After New MYQORZO Trial Data And Safety Outcomes - Yahoo Finance
Cytokinetics MYQORZO Data Sheds Light On oHCM Outlook And Valuation - simplywall.st
Cytokinetics (NASDAQ:CYTK) EVP Sells $104,300.27 in Stock - MarketBeat
Stifel reiterates Cytokinetics stock rating ahead of trial data By Investing.com - Investing.com Canada
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market - AOL.com
Cytokinetics (CYTK) Presents Findings on Aficamten for Cardiomyo - GuruFocus
Cytokinetics announces four presentations at the American College of Cardiology annual scientific session & expo - marketscreener.com
Cytokinetics Announces Four Presentations At The American College Of Cardiology Annual Scientific Session & Expo - TradingView
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual ... - nrtoday.com
Heart drug MYQORZO outperforms beta blocker in key HCM studies - Stock Titan
HighVista Strategies LLC Acquires 64,278 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
458,295 Shares in Cytokinetics, Incorporated $CYTK Purchased by Foresite Capital Management IV LLC - MarketBeat
Cinctive Capital Management LP Takes Position in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Acquired by Aquatic Capital Management LLC - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Boxer Capital Management LLC Acquires New Shares in Cytokinetics, Incorporated $CYTK - MarketBeat
Checkpoint Capital L.P. Invests $2.07 Million in Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics Highlights Early MYQORZO Momentum, Eyes Q2 nHCM Phase 3 Catalyst at Barclays Confab - MarketBeat
Cytokinetics Teases Q2 ACACIA-HCM Catalyst as MYQORZO Launch Gains Momentum at Leerink Conference - Yahoo Finance
Cytokinetics Teases Q2 Phase 3 ACACIA-HCM Readout as Myqorzo Launch Gains Traction at Citi Conference - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Sold by Melqart Asset Management UK Ltd - MarketBeat
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):